Atrial fibrillation--advances in drug therapy

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Science

Background:

• Global prevalence of atrial fibrillation (AF) is increasing, with projections indicating 5-15 million American cases by 2050.
• AF pathophysiology involves complex changes in ionic currents, atrial fibrosis, gap junctions, and cell membranes.
• Understanding these mechanisms drives the development of novel therapeutic agents.

Purpose of the Study:

• To review newly patented molecules for atrial fibrillation (AF) treatment.
• To highlight advances in drug discovery targeting AF's underlying pathophysiology.
• To discuss a range of novel therapeutic targets and their mechanisms of action.

Main Methods:

• Review of recently patented molecules relevant to atrial fibrillation (AF) therapy.
• Analysis of drugs targeting specific ionic currents and cellular components involved in AF.
• Categorization of new drug candidates based on their proposed mechanisms.

Main Results:

• Identification of newly patented molecules acting as sodium and potassium channel blockers.
• Discussion of drugs modulating gap junctions and intracellular calcium.
• Exploration of novel antagonists for stretch receptors and inhibitors of ischemic ion currents, alongside adenosine receptor agonists.

Conclusions:

• Significant progress has been made in discovering new drug therapies for atrial fibrillation (AF).
• Patented molecules offer diverse mechanisms to address the complex pathophysiology of AF.
• These advancements hold promise for improved management of the rising AF prevalence.